Theravance Biopharma, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Theravance Biopharma, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $20.00K.
- Theravance Biopharma, Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $30.00K.
- Theravance Biopharma, Inc. stock issued during period, value, new issues for fiscal 2024 was $99.00K.
- Theravance Biopharma, Inc. stock issued during period, value, new issues for fiscal 2021 was $108.18M, a 22.68% decline from fiscal 2020.
- Theravance Biopharma, Inc. stock issued during period, value, new issues for fiscal 2020 was $139.91M.
- Theravance Biopharma, Inc. stock issued during period, value, new issues for fiscal 2017 was $1.00K, a 100.00% decline from fiscal 2016.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $50.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $75.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $20.00K 10-Q · filed 2026-05-07 | $119.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $99.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $25.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $44.00K 10-Q · filed 2025-08-13 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $108.18M 10-K · filed 2023-03-01 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | |
| 2021-06-30 | $108.18M 10-Q · filed 2022-08-08 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $139.91M 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | |
| 2020-03-31 | $139.91M 10-Q · filed 2021-05-06 | |
| 2017-12-31 | $1.00K 10-K · filed 2020-02-27 | |
| 2016-12-31 | $253.03M 10-K · filed 2019-02-28 | |
| 2015-12-31 | $79.02M 10-K · filed 2018-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |